NCT06991114 - AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2029

Conditions

Refractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)Systemic Sclerosis (SSc)Rheumatoid Arthritis (RAIIMMyositisSclerodermaSjogren SyndromeSjogrens Disease

Interventions

DRUG

Allogeneic NK Cells

AlloNK, dosed after a conditioning regimen, combined with Rituximab.

Trial Locations (13)

28207

RECRUITING

Artiva Investigational Site Charlotte, Charlotte

28625

RECRUITING

Artiva Investigational Site Charlotte, Charlotte

33180

RECRUITING

Artiva Investigational Site Aventura, Aventura

33324

RECRUITING

Artiva Investigational Site Plantation, Plantation

33458

RECRUITING

Artiva Investigational Site Jupiter, Jupiter

35406

RECRUITING

Artiva Investigational Site Tuscaloosa, Tuscaloosa

37343

RECRUITING

Artiva Investigational Site Hixson, Hixson

60527

RECRUITING

Artiva Investigational Site Willowbrook, Willowbrook

75150

RECRUITING

Artiva Investigational Site Mesquite, Mesquite

76012

RECRUITING

Artiva Investigational Site Arlington, Arlington

77382

RECRUITING

Artiva Investigational Site Woodland, Woodland

77494

RECRUITING

Artiva Investigational Site Katy, Katy

91723

RECRUITING

Artiva Investigational Site Covina, Covina